Bromebrate sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584274

CAS#: 21739-91-3 (sodium)

Description: Bromebrate sodium, also known as Cytembena, is a nonmyelosuppressive drug that has received phase I--II trials.

Chemical Structure

img
Bromebrate sodium
CAS# 21739-91-3 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 584274
Name: Bromebrate sodium
CAS#: 21739-91-3 (sodium)
Chemical Formula: C11H8BrNaO4
Exact Mass: 305.95
Molecular Weight: 307.075
Elemental Analysis: C, 43.03; H, 2.63; Br, 26.02; Na, 7.49; O, 20.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 5711-40-0 (free acid)   21739-91-3 (sodium)    

Synonym: Bromebric acid sodium salt; Cytembena; NSC 104801;

IUPAC/Chemical Name: 2-Butenoic acid, 3-bromo-4-(4-methoxyphenyl)-4-oxo-, sodium salt, (2E)-

InChi Key: DVDCIQWIGOVWEX-MLBSPLJJSA-M

InChi Code: InChI=1S/C11H9BrO4.Na/c1-16-8-4-2-7(3-5-8)11(15)9(12)6-10(13)14;/h2-6H,1H3,(H,13,14);/q;+1/p-1/b9-6+;

SMILES Code: O=C([O-])/C=C(Br)\C(C1=CC=C(OC)C=C1)=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 307.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Havlík I, Janků I. Studium kinetiky 14C-cytembeny po nitrozilním podání u králíků s pouzitím autoradiografie na tenké vrstvĕ [A study of the kinetics of 14C-cytembena after intravenous administration in rabbits using thin-layer autoradiography]. Cesk Farm. 1983 Sep;32(7):241-4. Czech. PMID: 6688969.


2: Georgoulias V, Misset JL, Ribaud P, Machover D, De Vassal F, Dorval T, Musset M, Schwarzenberg L, Reizenstein P, Mathe G, Gaget H. Doxorubicin, vincristine, bleomycin, cytembena and cisplatin as combination chemotherapy for squamous cell lung cancer. Anticancer Res. 1983 Mar-Apr;3(2):107-10. PMID: 6189445.


3: Huff J. Cytembena: Condensation of the Carcinogenesis Bioassay Technical Report. Environ Health Perspect. 1982 Nov;45:201-3. PMID: 17539167; PMCID: PMC1568995.


4: Mayo JR, DeSouza JJ, Malspeis L, Feller DR. Evidence for the nonenzymatic and irreversible binding of cytembena to rat liver microsomes in vitro. Biochem Pharmacol. 1982 Oct 15;31(20):3201-5. doi: 10.1016/0006-2952(82)90550-0. PMID: 6897357.


5: Ronot X, Adolphe M, Kuch D, Jaffray P, Lechat P, Deysson G. Effect of sodium cis-beta-4-methoxybenzoyl-beta-bromacrylate (Cytembena) on HeLa cell kinetics. Cancer Res. 1982 Aug;42(8):3193-5. PMID: 6896468.


6: Cardone A, Tolino A, Di Serio C, Zarcone R, Borruto Caracciolo G, Ronsini S. Cytembena and cis-platinum in combination for advanced stage ovarian carcinoma treatment. Clin Exp Obstet Gynecol. 1982;9(2):84-94. PMID: 6897625.


7: National Toxicology Program. Carcinogenesis Bioassay of Cytembena (CAS No. 21739-91-3). Natl Toxicol Program Tech Rep Ser. 1981 May;207:1-113. PMID: 12778228.


8: Ronot X, Kuch D, Hecquet C, Adolphe M, Lechat P, Deysson G. Effet inhibiteur du Cytembena (cis-beta-methoxybenzoyl-beta-bromacrylate de sodium) sur la cinétique des cellules HeLa en culture [Inhibitory effect of cytembena (sodium- cis-beta-methoxybenzoyl-beta-bromoacrylate) on the cell kinetics of HeLa cells in culture]. C R Seances Acad Sci D. 1980 Dec 8;291(12):961-4. French. PMID: 6784949.


9: Matĕjková E, Jandová A, Pezlarová A, Rezábek K. Vliv cytembeny cyklofosfamidu a jejich kombinace na katalytickou aktivitu plazmatických enzymů krys zdravých a krys s Yoshidovým sarkomem [Effect of cytembena, cyclophosphamide and their combination on the catalytic activity of plasma enzymes of healthy rats and rats with Yoshida's sarcoma (author's transl)]. Sb Lek. 1980;82(11-12):356-62. Czech. PMID: 6894040.


10: Neidhart JA, Staubus AE, Young D, Balcerzak SP, Malspes IL. Oral cytembena absorption and phase I--II studies. Cancer Treat Rep. 1978 Mar;62(3):401-4. PMID: 348307.


11: Edmonson JH, Decker DG, Malkasian GD, Webb MJ, Jorgensen EO. Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication. J Natl Cancer Inst. 1977 Dec;59(6):1619-20. doi: 10.1093/jnci/59.6.1619. PMID: 579188.


12: A phase II clinical trial of cytembena. Clinical screening group of E.O.R.T.C. Biomedicine. 1977 Dec;26(6):392-5. PMID: 342004.


13: Von Hoff DD, Rozencweig M, Muggia FM. Cytembena: an anticancer drug with an unique structure. Biomedicine. 1977 Dec;26(6):388-92. PMID: 342003.


14: Berger NA, Weber G. Description of a permeable eukaryotic cell system to study agents affecting DNA synthesis: demonstration that cytembena is a direct inhibitor of replicative DNA synthesis. J Natl Cancer Inst. 1977 Apr;58(4):1167-9. doi: 10.1093/jnci/58.4.1167. PMID: 576624.


15: Mitoma C, Saito T, Howd RA. Metabolic disposition of cytembena in rats and dogs. Xenobiotica. 1977 Mar;7(3):165-79. doi: 10.3109/00498257709036248. PMID: 576751.


16: Berndt WO. A further characterization of cytembena-induced nephrotoxicity. Toxicol Appl Pharmacol. 1977 Feb;39(2):207-17. doi: 10.1016/0041-008x(77)90154-5. PMID: 576748.


17: Novotná J, Jandová A, Janousková M, Laurová L, Skoda V. Hladiny DNA a RNA v tkáni karcinomů colli uteri pred a po podání Cytembeny [Levels of DNA and RNA in the carcinomatous tissue of the collum uteri before and after application of Cytembena (author's transl)]. Cesk Gynekol. 1976 Dec;41(10):733-4. Czech. PMID: 1036977.


18: Falkson HC, Falkson G. Phase II trial of cytembena in patients with advanced ovarian and breast cancer. Cancer Treat Rep. 1976 Nov;60(11):1655-8. PMID: 1037286.


19: Goetz P, Srám RJ, Kodýková I, Dohnalová J, Dostálová O, Bartova J. Relationship between experimental results in mammals and man. II. Cytogenetic analysis of bone-marrow cells after treatment of cytembena and cyclophosphamide- cytembena combination. Mutat Res. 1976 Nov 1;41(1 spel. no):143-52. doi: 10.1016/0027-5107(76)90084-1. PMID: 1037016.


20: Baker LH, Samson MK, Izbicki RM. Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas. Cancer Treat Rep. 1976 Sep;60(9):1389-91. PMID: 189923.